AtriCure, Inc. reported a significant increase in financial performance for the third quarter of 2025, with total revenue reaching $134.3 million, a 15.8% increase from $115.9 million in the same period of 2024. For the nine months ending September 30, 2025, revenue totaled $394.0 million, up 15.5% from $341.0 million year-over-year. The company’s gross profit for the quarter was $101.3 million, yielding a gross margin of 75.5%, compared to 74.9% in the prior year. Despite the revenue growth, AtriCure reported a net loss of $267,000 for the quarter, an improvement from a net loss of $7.9 million in Q3 2024.
The company’s operational metrics showed notable changes, particularly in product lines. Revenue from appendage management products increased by 21.5%, while pain management products saw a 27.7% rise. However, sales from minimally invasive ablation products declined by 33.2%, attributed to a shift in physician preference towards newer PFA catheter treatments. International sales also grew by 22.0%, indicating strong demand across various geographic regions.
Strategically, AtriCure has focused on product innovation and clinical research. The launch of the cryoICE® cryoXT™ probe in the U.S. during Q3 2025 is aimed at enhancing pain management solutions for amputation patients. The company is also advancing its clinical trials, including the LeAAPS trial, which has enrolled 6,500 patients across 137 centers globally, and the BoxX-NoAF trial, which recently began patient enrollment. These initiatives are part of AtriCure's broader strategy to expand its market presence and product offerings.
As of September 30, 2025, AtriCure reported total assets of $635.4 million, up from $609.3 million at the end of 2024. The company’s cash and cash equivalents increased to $147.9 million, reflecting improved cash flow from operations, which provided $37.3 million in the first nine months of 2025, compared to $6.4 million in the same period of 2024. The company’s employee headcount has also grown, contributing to increased personnel costs in both research and development and selling, general, and administrative expenses.
Looking ahead, AtriCure anticipates continued growth driven by its strategic initiatives in product development and market expansion. The company remains focused on enhancing its product portfolio and increasing adoption rates among healthcare providers, despite facing competition from new entrants in the market. AtriCure's management expressed optimism about the future, emphasizing the importance of ongoing clinical research and training programs to support product adoption and improve patient outcomes.
About AtriCure, Inc.
AtriCure, Inc. develops and markets medical devices for the surgical treatment of atrial fibrillation (Afib), left atrial appendage management (LAAM), and post-operative pain management. Its product portfolio includes radiofrequency and cryoablation systems, the AtriClip LAA exclusion device, and cryo nerve block probes. Serving cardiothoracic surgeons and electrophysiologists globally, AtriCure’s technologies offer clinically proven, less invasive solutions to improve patient outcomes and reduce stroke risk and post-surgical pain.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.